Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 21 citing articles:

Evaluating the antioxidant, anti‐inflammatory, and neuroprotective potential of fruiting body and mycelium extracts from edible yellow morel (Morchella esculenta L. Pers.)
Rida Haider, Luisa Agnello, Shahid Masood Shah, et al.
Journal of Food Science (2025) Vol. 90, Iss. 1
Open Access | Times Cited: 2
Passive Alzheimer’s immunotherapy: A promising or uncertain option?
Poul Flemming Høilund‐Carlsen, Mona‐Elisabeth Revheim, Tommaso Costa, et al.
Ageing Research Reviews (2023) Vol. 90, pp. 101996-101996
Open Access | Times Cited: 31
Mesenchymal and Neural Stem Cell-Derived Exosomes in Treating Alzheimer’s Disease
Hongmin Wang, Christa C. Huber, Xiaoping Li
Bioengineering (2023) Vol. 10, Iss. 2, pp. 253-253
Open Access | Times Cited: 23
New insights into butyrylcholinesterase: Pharmaceutical applications, selective inhibitors and multitarget-directed ligands
Tian‐Yu Sun, Tengfei Zhen, Chrisanta Hamis Harakandi, et al.
European Journal of Medicinal Chemistry (2024) Vol. 275, pp. 116569-116569
Closed Access | Times Cited: 14
Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?
Laura Marinela Ailioaie, Constantin Ailioaie, Gerhard Litscher
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 916-916
Open Access | Times Cited: 22
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Allison B. Reiss, Dalia Muhieddine, Berlin Jacob, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1084-1084
Open Access | Times Cited: 18
Dementia Medications and Their Association with Pain Medication Use in Medicare Beneficiaries with Alzheimer’s Disease/Alzheimer’s Disease-Related Dementias and Chronic Pain
Sadaf Arefi Milani, Jordan Westra, Yong Fang Kuo, et al.
Drugs & Aging (2025)
Open Access
Unraveling the Complexity of Alzheimer’s Disease: Insights into Etiology and Advancements in Treatment Strategies
Bakhtawar Khan, Muhammad Khalid Iqbal, Muhammad Ajmal Khan, et al.
Journal of Molecular Neuroscience (2025) Vol. 75, Iss. 2
Closed Access
Impact of Peptide Transport and Memory Function in the Brain
Lihong Cheng, Caiyue Shi, Xixi Li, et al.
Nutrients (2024) Vol. 16, Iss. 17, pp. 2947-2947
Open Access | Times Cited: 2
The assessment of pharmacokinetics and neuroprotective effect of berberine hydrochloride-embedded albumin nanoparticles via various administration routes: comparative in-vivo studies in rats
Hany G. Attia, Maha E. Elmataeeshy, Mohamed Aleraky, et al.
Journal of Microencapsulation (2024), pp. 1-25
Closed Access | Times Cited: 2
Dementia and neurodegenerative diseases: What is known and what is promising at the cellular and molecular level
Olesia F. Moroz, В. И. Кравченко, Bohdan O. Kushch, et al.
Basic & Clinical Pharmacology & Toxicology (2024)
Closed Access | Times Cited: 2
Repurposing Diltiazem for Its Neuroprotective Anti-Dementia Role against Intra-Cerebroventricular Streptozotocin-Induced Sporadic Alzheimer’s Disease-Type Rat Model
Ramesh Alluri, Eswar Kumar Kilari, Praveen Kumar Pasala, et al.
Life (2023) Vol. 13, Iss. 8, pp. 1688-1688
Open Access | Times Cited: 5
Focus on Neurochemistry Led to the Cholinergic Hypothesis of Alzheimer’s Disease
Christian Behl
Springer eBooks (2023), pp. 73-91
Closed Access | Times Cited: 4
Repurposing Diltiazem for Its Neuroprotective Anti-dementia Role Against Intra-Cerebroventricular Streptozotocin-Induced Sporadic Alzheimer’s Disease-Type Rat Model
Ramesh Alluri, Spandana Rajendra Kopalli, Eswar Kumar Kilari, et al.
(2023)
Open Access | Times Cited: 2
Editorial: Therapeutic neuromodulation for aging-related disorders associated with the autonomic nervous system
Stephanie Chee Yee Tjen-A-Looi, Liang‐Wu Fu, Shaista Malik, et al.
Frontiers in Aging Neuroscience (2024) Vol. 16
Open Access
Effect of Socialization on Alzheimer’s Disease During the COVID-19 Pandemic
Ricardo Maldonado‐Puebla, Parth M Raina, Deepesh Khanna
Cureus (2024)
Open Access
Potentiality of Marine Microbial Metabolites in the Remedy of Alzheimer’s Disease: A Comprehensive Review
Srijita Paul, Mouli Dey, Bishnupriya Roy, et al.
Proceedings of the Zoological Society (2024) Vol. 77, Iss. 3, pp. 293-303
Closed Access
Research Progress of Neurogenic Exosomes in the Treatment of Alzheimer’s Disease
思柔 黄
Advances in Clinical Medicine (2024) Vol. 14, Iss. 09, pp. 1034-1041
Closed Access
Amentoflavone for treating cardiocerebrovascular diseases and neurological disorders
Zhang Hang, Yunfei Ban, De-mei Li, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Neurodegenerative Disorders: Types, Classification, and Basic Concepts
Jagdish Chand, Gomathy Subramanian
(2024), pp. 31-40
Closed Access
Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment
Jinwei Zhang
Inflammation Research (2023) Vol. 72, Iss. 9, pp. 1873-1876
Closed Access | Times Cited: 1
Potential of Monoclonal Antibody (mAb) as Alternative Treatment of Alzheimer: A Sytematic Scoping Review
Nuraulia Aghnia Armansyah, Azalia Melati Putri, Wafiq Nurul Azizah, et al.
JURNAL PENDIDIKAN KEPERAWATAN INDONESIA (2023) Vol. 9, Iss. 1, pp. 79-82
Open Access
Page 1

Scroll to top